Paclitaxel

製品コードS1150 別名：NSC 125973

Paclitaxel化学構造

分子量(MW)：853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

サイズ 価格(税別)  
JPY 15106.00
JPY 11620.00
JPY 44820.00
お問い合わせ バルク問合せ

文献中Selleckの製品使用例(22)

カスタマーフィードバック(6)

  • (F) Kaplan-Meier curves are shown for all groups described: no hydrogel, a hydrogel loaded with paclitaxel, or a hydrogel loaded with doxorubicin. The number of mice per group (n) and median survival (ms) are listed. The experiment was performed at least three times.

    Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916. Paclitaxel purchased from Selleck.

    Effect of tivantinib on the mitotic index was compared with the antimitotic drugs paclitaxel and vinblastine after overnight treatment of the HLE cell line with two different concentrations of each drug.

    Clin Cancer Res, 2017, 23(15):4364-4375. Paclitaxel purchased from Selleck.

  • Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

    ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

    Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

    Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.

  • Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

    PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

    Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

    RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

製品安全説明書

Microtubule Associated阻害剤の選択性比較

生物活性

製品説明 Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
ターゲット
Microtubule (human endothelial cells) [1]
0.1 pM
体外試験

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]
細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlu4TWM2OD1yLkCwNFI5PyEQvF2= M3PmSnNCVkeHUh?=
LC-2-ad MmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMECwN|E4KM7:TR?= MkDDV2FPT0WU
RL95-2 M3PFc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk[5TWM2OD1yLkCwNFY3QCEQvF2= MYXTRW5ITVJ?
MZ1-PC Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMECwO|I6KM7:TR?= M3OxTnNCVkeHUh?=
TE-8 NYjJXoFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrMTIVNUUN3ME2wMlAxOTF5IN88US=> M{PUZnNCVkeHUh?=
SW954 M2\ucWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vFfmlEPTB;MD6wNFEyQSEQvF2= NWHKZ3VmW0GQR1XS
TE-11 M1rrSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwMECxNlMh|ryP MXLTRW5ITVJ?
PSN1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPINZNPUUN3ME2wMlAxOTNizszN M{jhVXNCVkeHUh?=
MOLT-4 NH[4d2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYW0dHBiUUN3ME2wMlAxOTR7IN88US=> MVnTRW5ITVJ?
697 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXnTnRqUUN3ME2wMlAxOTVizszN NFHQOZBUSU6JRWK=
ETK-1 Mnm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\MTWM2OD1yLkCwNVUzKM7:TR?= MYHTRW5ITVJ?
TE-10 NUTnWY51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGn0TJNKSzVyPUCuNFAyPTRizszN MWPTRW5ITVJ?
HUTU-80 Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrCemNKSzVyPUCuNFAyPjhizszN MX3TRW5ITVJ?
NTERA-S-cl-D1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3iTWM2OD1yLkCwNlA6KM7:TR?= MlXFV2FPT0WU
MFH-ino NVvQO|Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXpN4pmUUN3ME2wMlAxOjZ6IN88US=> MUnTRW5ITVJ?
IA-LM MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfjTWM2OD1yLkCwNlgh|ryP NGDvbIRUSU6JRWK=
MC116 NF3UPIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\kc5hKSzVyPUCuNFAzQDlizszN MoLQV2FPT0WU
RKO M4rmb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXsOGdPUUN3ME2wMlAxOjl6IN88US=> M4jBRXNCVkeHUh?=
MRK-nu-1 M{[zZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwMECyPVkh|ryP MkHuV2FPT0WU
VA-ES-BJ NH\BellIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NESwV2pKSzVyPUCuNFA{KM7:TR?= MmjtV2FPT0WU
KALS-1 MnvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHD[2lUUUN3ME2wMlAxOzB6IN88US=> MX7TRW5ITVJ?
BB30-HNC MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XvVmlEPTB;MD6wNFMyPCEQvF2= NIT0b3FUSU6JRWK=
ACN NHLMXpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwMECzNVYh|ryP MnnIV2FPT0WU
TE-9 NHf5e2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWqz[Y9LUUN3ME2wMlAxOzJ4IN88US=> MnuxV2FPT0WU
SIG-M5 NFfV[4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwMECzNlch|ryP MVHTRW5ITVJ?
no-10 MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwMECzOlIh|ryP M130[3NCVkeHUh?=
EW-1 M4XDTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwMECzO|Eh|ryP MUfTRW5ITVJ?
SK-LMS-1 NInrS2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXid4J7UUN3ME2wMlAxPDBzIN88US=> M4X6UXNCVkeHUh?=
GT3TKB NU\jNYxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwMEC0N|Qh|ryP MkDyV2FPT0WU
ES4 MmnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGn4Z4pKSzVyPUCuNFA1PDlizszN MVLTRW5ITVJ?
IMR-5 NFX0RY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWG0fXVKUUN3ME2wMlAxPDVizszN NH;jWW9USU6JRWK=
NCI-H1648 NHWwdnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn23TWM2OD1yLkCwOFY6KM7:TR?= NXzNeZJ1W0GQR1XS
MV-4-11 NGDONGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLYTWM2OD1yLkCwOFc2KM7:TR?= MXnTRW5ITVJ?
SK-UT-1 NXXuO5RLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjoTWM2OD1yLkCwOFgh|ryP NUew[Xc{W0GQR1XS
NB13 MmryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjsTWM2OD1yLkCwOFkyKM7:TR?= MnTwV2FPT0WU
DJM-1 NEXvb2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGe0UJBKSzVyPUCuNFA2OyEQvF2= NGDOWJJUSU6JRWK=
ES8 M2XCeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMEC1N|gh|ryP M2fhZnNCVkeHUh?=
TE-6 NF20TplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTBwMEC1O{DPxE1? MYXTRW5ITVJ?
KS-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{flcmlEPTB;MD6wNFU5OiEQvF2= NILWSY1USU6JRWK=
TE-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nuemlEPTB;MD6wNFYxPiEQvF2= MV\TRW5ITVJ?
ATN-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\KU5dKSzVyPUCuNFA3ODlizszN NXXjVlZCW0GQR1XS
A4-Fuk NFXqeHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYO2S|R4UUN3ME2wMlAxPjFzIN88US=> MWfTRW5ITVJ?
ALL-PO MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2f5[mlEPTB;MD6wNFY{KM7:TR?= NF;5[5pUSU6JRWK=
BE-13 MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\iPZd2UUN3ME2wMlAxPjN4IN88US=> NVX6WHpzW0GQR1XS
KM12 MljUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfzTWM2OD1yLkCwOlM4KM7:TR?= MVvTRW5ITVJ?
NOS-1 NWPi[VduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrP[IVKSzVyPUCuNFA3PSEQvF2= NH[zV4VUSU6JRWK=
SW962 M{HTWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[3TWM2OD1yLkCwOlYzKM7:TR?= MkHFV2FPT0WU
OCUB-M NYDUfFNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HTOmlEPTB;MD6wNFY3OiEQvF2= NH[x[olUSU6JRWK=
NCI-H510A MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDoR4ZKSzVyPUCuNFA3PjVizszN M1G2d3NCVkeHUh?=
EW-16 M2Trfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwMEC2PVQh|ryP MmPXV2FPT0WU
KGN MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwMEC3NVIh|ryP NXzJdIt1W0GQR1XS
LS-411N NXW2d3BmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwMEC3NVch|ryP M3fkUnNCVkeHUh?=
Becker MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwMEC3NkDPxE1? MXrTRW5ITVJ?
HC-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwMEC3NlEh|ryP NVywVJJVW0GQR1XS
CESS NIPJ[3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGSzR2ZKSzVyPUCuNFA4OzdizszN Mom2V2FPT0WU
KURAMOCHI NVj5eIxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHf6[nlKSzVyPUCuNFA4PDhizszN NFHoNlFUSU6JRWK=
TGBC24TKB MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTtSlhKSzVyPUCuNFA4PTJizszN NH;ud45USU6JRWK=
SW982 M2ezOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2j5e2lEPTB;MD6wNFc3PiEQvF2= MVvTRW5ITVJ?
HCE-4 Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfZVFdKSzVyPUCuNFA4PjdizszN NY\jb5F2W0GQR1XS
LOUCY MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwMEC3O|Uh|ryP NFLKemtUSU6JRWK=
8-MG-BA Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDNTWM2OD1yLkCwO|k3KM7:TR?= MlzRV2FPT0WU
HT-144 NV;QTXB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnUZnBJUUN3ME2wMlAxQCEQvF2= NITPNpZUSU6JRWK=
LXF-289 M{XjTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnsXG1KSzVyPUCuNFA5OThizszN NUjCTJc2W0GQR1XS
RS4-11 NYLKNmY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvhfIJ3UUN3ME2wMlAxQDN4IN88US=> Mni2V2FPT0WU
DEL NXTvRVh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\wbWFIUUN3ME2wMlAxQDR3IN88US=> NXXHd|VnW0GQR1XS
OCI-AML2 M4O4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnkTWM2OD1yLkCwPFUzKM7:TR?= NIn6e|BUSU6JRWK=
CCRF-CEM NFvkN3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkf6TWM2OD1yLkCwPFcyKM7:TR?= NF:xe5NUSU6JRWK=
A388 MkSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIC3PJRKSzVyPUCuNFA5PzRizszN MmLTV2FPT0WU
KNS-42 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETHTHhKSzVyPUCuNFA5QTFizszN NXjrV|ZFW0GQR1XS
OVCAR-4 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;hTWM2OD1yLkCwPVA1KM7:TR?= NFf1eJpUSU6JRWK=
NCI-H1355 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LWPGlEPTB;MD6wNFkyPCEQvF2= MX;TRW5ITVJ?
BL-70 M3:5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoD0TWM2OD1yLkCwPVMh|ryP NEfKc5RUSU6JRWK=
BL-41 M4\YN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\KV|NEUUN3ME2wMlAxQTN2IN88US=> MXfTRW5ITVJ?
A101D MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[0bmlEPTB;MD6wNFk3KM7:TR?= NYfrT456W0GQR1XS
HL-60 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXX0XWg4UUN3ME2wMlAxQTZ4IN88US=> M1e4UnNCVkeHUh?=
COR-L279 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXnTWM2OD1yLkCwPVk6KM7:TR?= MlLHV2FPT0WU
NCI-SNU-16 M1ra[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLRdmRKSzVyPUCuNFExODhizszN Mk\VV2FPT0WU
Calu-6 MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGH1boNKSzVyPUCuNFExOTJizszN MVfTRW5ITVJ?
SR MkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGr3RmtKSzVyPUCuNFExOjZizszN MlnlV2FPT0WU
QIMR-WIL M2nVXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HMOmlEPTB;MD6wNVA{OyEQvF2= MmmyV2FPT0WU
LB647-SCLC MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3frdmlEPTB;MD6wNVA2OSEQvF2= Mmm0V2FPT0WU
RPMI-8226 MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vQVWlEPTB;MD6wNVExOiEQvF2= MlPPV2FPT0WU
SK-PN-DW M3\reGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnQb5FwUUN3ME2wMlAyOTF{IN88US=> M{DYfHNCVkeHUh?=
SF268 NXfSWJdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwMEGxOVEh|ryP NXvLTHJzW0GQR1XS
HD-MY-Z NFHUXXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i3WmlEPTB;MD6wNVE3OyEQvF2= MY\TRW5ITVJ?
DOHH-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XyRWlEPTB;MD6wNVIxOyEQvF2= M{jWbnNCVkeHUh?=
SCC-3 NX3OZlRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[2fFZKSzVyPUCuNFEzODRizszN NEjIXoRUSU6JRWK=
ST486 NVzTPWV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\Yem5FUUN3ME2wMlAyOjB2IN88US=> MWXTRW5ITVJ?
NALM-6 MmrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPl[pNKSzVyPUCuNFEzOTRizszN NIDYfYVUSU6JRWK=
NCI-H1436 NXj2TmVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPUTWM2OD1yLkCxNlMyKM7:TR?= NWr6fG1KW0GQR1XS
KE-37 M2LZNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHz5fYZKSzVyPUCuNFEzOzRizszN MXrTRW5ITVJ?
RPMI-8402 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\wTWM2OD1yLkCxNlU3KM7:TR?= M4LUfHNCVkeHUh?=
RXF393 NHfWSZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrvTWM2OD1yLkCxNlU4KM7:TR?= MXzTRW5ITVJ?
KARPAS-45 M{fnV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkL6TWM2OD1yLkCxNlch|ryP Mnf6V2FPT0WU
HOP-62 M2HxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMEGyO|Yh|ryP MoPIV2FPT0WU
ES1 Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;qOnBnUUN3ME2wMlAyOjh6IN88US=> M3HWZnNCVkeHUh?=
L-363 MlzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nNOmlEPTB;MD6wNVM2OSEQvF2= MVfTRW5ITVJ?
GI-1 M4rseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vjR2lEPTB;MD6wNVM4OyEQvF2= MU\TRW5ITVJ?
CTV-1 NXfObYpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnX5TWM2OD1yLkCxOFc5KM7:TR?= NV21XYtWW0GQR1XS
TE-5 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEntRYdKSzVyPUCuNFE1QTZizszN M1r3O3NCVkeHUh?=
SNU-C2B MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX5UVQ3UUN3ME2wMlAyPDl4IN88US=> M4\QU3NCVkeHUh?=
K-562 MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwMEG1NVYh|ryP Ml3zV2FPT0WU
SNB75 NV;EOYJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVf2TVl7UUN3ME2wMlAyPTRizszN M2Tkb3NCVkeHUh?=
MOLT-13 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGKwS5hKSzVyPUCuNFE3OzdizszN NXXlN5J[W0GQR1XS
LS-123 NInIfVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwMEG2OlQh|ryP NH\2d2NUSU6JRWK=
NCI-SNU-5 MmfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mle1TWM2OD1yLkCxO|AyKM7:TR?= MXnTRW5ITVJ?
Daudi NUTa[5drT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMEG3NFgh|ryP MUnTRW5ITVJ?
A253 NEjENmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjhOpFKSzVyPUCuNFE4OzhizszN MlzIV2FPT0WU
TGBC1TKB MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{flOWlEPTB;MD6wNVc2OiEQvF2= M2XRR3NCVkeHUh?=
SJSA-1 NWD5WYxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPzS4t5UUN3ME2wMlAyPzZ5IN88US=> M2rXN3NCVkeHUh?=
NCCIT NWTy[XhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PiSWlEPTB;MD6wNVc3QSEQvF2= MmntV2FPT0WU
NCI-H69 NXT6dZo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfPTWM2OD1yLkCxO|c5KM7:TR?= NVPidGhmW0GQR1XS
SH-4 NXj2Slg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17CcGlEPTB;MD6wNVg6PSEQvF2= NV;Be4N7W0GQR1XS
HCC1187 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwMEG5NlQh|ryP NUn1VGxmW0GQR1XS
HCC1599 M1XMN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HxSmlEPTB;MD6wNlAzKM7:TR?= NF7TVnBUSU6JRWK=
ONS-76 NUG3NGhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwMEKwN|Yh|ryP NXPkN2JZW0GQR1XS
KU812 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwMEKwN|kh|ryP NXHSTlJVW0GQR1XS
ML-2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zET2lEPTB;MD6wNlA1PyEQvF2= NXzabVZGW0GQR1XS
HCE-T MkTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwMEKwPVIh|ryP MY\TRW5ITVJ?
NCI-H446 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17KdGlEPTB;MD6wNlEyOiEQvF2= MULTRW5ITVJ?
RPMI-6666 NH;FcZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXwTWM2OD1yLkCyNVQ6KM7:TR?= NXn6UlhCW0GQR1XS
MOLT-16 MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzETWM2OD1yLkCyNVU{KM7:TR?= MmPvV2FPT0WU
JiyoyeP-2003 NGrINJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\DboE{UUN3ME2wMlAzOTd4IN88US=> M3TEZnNCVkeHUh?=
MHH-PREB-1 NEXJZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fqd2lEPTB;MD6wNlE6OSEQvF2= MWDTRW5ITVJ?
MC-CAR M2DYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETr[4JKSzVyPUCuNFI{OjZizszN MYHTRW5ITVJ?
BC-3 NFzkR4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnVOWh[UUN3ME2wMlAzOzR2IN88US=> M4XHcXNCVkeHUh?=
KINGS-1 M1LPVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGT3T5NKSzVyPUCuNFI{PTVizszN NHfTd|FUSU6JRWK=
PF-382 M1HnTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PvNWlEPTB;MD6wNlM4QCEQvF2= M{DyS3NCVkeHUh?=
J-RT3-T3-5 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEK4cHpKSzVyPUCuNFI{QDNizszN M3XyWXNCVkeHUh?=
SF539 MkHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NED0coFKSzVyPUCuNFI1ODFizszN M2fBbHNCVkeHUh?=
LB831-BLC MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mon2TWM2OD1yLkCyOFg2KM7:TR?= NVrhR3d1W0GQR1XS
DMS-114 MkX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfJN415UUN3ME2wMlAzPTB{IN88US=> MX3TRW5ITVJ?
LB1047-RCC MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHqSHdLUUN3ME2wMlAzPTFizszN MkfPV2FPT0WU
LB771-HNC M1vzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2n3e2lEPTB;MD6wNlU{PCEQvF2= Mnz5V2FPT0WU
BB65-RCC MoD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoflTWM2OD1yLkCyOVM1KM7:TR?= NVH1OFJUW0GQR1XS
BV-173 M16xXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[xeoRKSzVyPUCuNFI2PTRizszN NWLR[pg2W0GQR1XS
ARH-77 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjHU4pQUUN3ME2wMlAzPjBzIN88US=> MoDpV2FPT0WU
IST-MEL1 NXnXZnBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXFTWM2OD1yLkCyOlI{KM7:TR?= NWSxUY51W0GQR1XS
NB1 M1nacWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLmTWM2OD1yLkCyOlg4KM7:TR?= NYPFZYNpW0GQR1XS
EoL-1-cell Mm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkm1TWM2OD1yLkCyOlg5KM7:TR?= M3vmUHNCVkeHUh?=
KY821 MoS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jaO2lEPTB;MD6wNlY6PyEQvF2= NX\JSFBzW0GQR1XS
CMK Mor0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvXTWM2OD1yLkCyO|M1KM7:TR?= M2SydnNCVkeHUh?=
NCI-H2126 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjPZ2xKSzVyPUCuNFI4PjhizszN NUfKRnQ6W0GQR1XS
NCI-H526 M3zOXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\BcmlEPTB;MD6wNlg6OSEQvF2= NFf4ZXVUSU6JRWK=
COLO-684 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;2NWlEPTB;MD6wNlkxQCEQvF2= NYLQNJZyW0GQR1XS
NCI-H747 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwMEK5N|Mh|ryP NWTIV5dsW0GQR1XS
JAR NInRRVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrXc|NKSzVyPUCuNFI6PDZizszN MUXTRW5ITVJ?
MEG-01 NF3qT21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDkfHlKSzVyPUCuNFI6PzhizszN MmjNV2FPT0WU
MONO-MAC-6 M4P3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHLNJdKSzVyPUCuNFMxOjNizszN Ml\3V2FPT0WU
IST-SL1 NE\LOIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwMEOwOFIh|ryP M1G2SXNCVkeHUh?=
CPC-N MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDyOJNKSzVyPUCuNFMxPzlizszN NXH5SXZpW0GQR1XS
NCI-H1963 NVTKXINoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGC0[lJKSzVyPUCuNFMyOzFizszN NHjEZ2lUSU6JRWK=
K052 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zNZ2lEPTB;MD6wN|I1PyEQvF2= Mmq0V2FPT0WU
KM-H2 M2TpVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMEOzNFch|ryP NGXlXItUSU6JRWK=
TE-12 MofPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTDZXdKSzVyPUCuNFM{ODlizszN NITUZZhUSU6JRWK=
TK10 M1jLU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPJTWM2OD1yLkCzN|U3KM7:TR?= MVzTRW5ITVJ?
NMC-G1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1O5dGlEPTB;MD6wN|Q2OiEQvF2= M{nweXNCVkeHUh?=
no-11 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17kRWlEPTB;MD6wN|Q4QCEQvF2= NYDaSWVWW0GQR1XS
NCI-H524 NX62Tnl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTaTWM2OD1yLkCzOVI6KM7:TR?= MnrmV2FPT0WU
MHH-CALL-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Xyd2lEPTB;MD6wN|U3OiEQvF2= MWnTRW5ITVJ?
GB-1 NWflNZRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoCyTWM2OD1yLkCzOkDPxE1? MXPTRW5ITVJ?
OPM-2 NGW1co9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPhdZVKSzVyPUCuNFM3PzNizszN NHLMXYhUSU6JRWK=
RH-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXT2elEyUUN3ME2wMlA{QDF7IN88US=> M2XhUHNCVkeHUh?=
NCI-H64 NYXXcpFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHZSmQzUUN3ME2wMlA{QDV5IN88US=> M{PxfHNCVkeHUh?=
EVSA-T NIO4bGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LSU2lEPTB;MD6wN|kzOyEQvF2= M2ruPXNCVkeHUh?=
KARPAS-299 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnBXW5bUUN3ME2wMlA{QThizszN M3[xXnNCVkeHUh?=
MZ7-mel NHvENGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjBTWM2OD1yLkC0NFQh|ryP Mn76V2FPT0WU
LB373-MEL-D MmD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjP[5ZmUUN3ME2wMlA1OTB3IN88US=> MVvTRW5ITVJ?
HEL NF3H[YRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nFeWlEPTB;MD6wOFE1KM7:TR?= Mm\kV2FPT0WU
SW872 M{WyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\JTWM2OD1yLkC0NlEh|ryP MVPTRW5ITVJ?
DU-4475 MnT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTuXnpnUUN3ME2wMlA1OjR2IN88US=> MliyV2FPT0WU
IST-SL2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{ewV2lEPTB;MD6wOFI4PSEQvF2= M2nSN3NCVkeHUh?=
NCI-H82 M3HkWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwMESzNFch|ryP MXvTRW5ITVJ?
LC4-1 NVzRSY9wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjlTWM2OD1yLkC0N|UyKM7:TR?= MUPTRW5ITVJ?
HDLM-2 M{LVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMESzPVIh|ryP MlnMV2FPT0WU
MMAC-SF M3zv[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmOwTWM2OD1yLkC0OVM1KM7:TR?= M{DxdnNCVkeHUh?=
L-540 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwMES2N|kh|ryP M3n4XHNCVkeHUh?=
MZ2-MEL NFrUOXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwMES3OFIh|ryP MkLYV2FPT0WU
LU-134-A MnPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwMES3O|Mh|ryP NHy4d3RUSU6JRWK=
UACC-257 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXWb5NDUUN3ME2wMlA1QDR7IN88US=> MVrTRW5ITVJ?
NCI-H1581 NUDV[VFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3nbJhjUUN3ME2wMlA1QTV|IN88US=> NXjwOY5ZW0GQR1XS
NB17 NYrQTmtET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTyWVM2UUN3ME2wMlA1QTd7IN88US=> MnrNV2FPT0WU
SBC-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnjZnJIUUN3ME2wMlA2ODR{IN88US=> M1fSZXNCVkeHUh?=
TALL-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjybWI5UUN3ME2wMlA2ODR3IN88US=> NXzJdYNXW0GQR1XS
NCI-H1304 NYDrfFN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknCTWM2OD1yLkC1NlA5KM7:TR?= NWrrRohbW0GQR1XS
NEC8 NEX5d41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrDWVFKSzVyPUCuNFUzQDZizszN Mln6V2FPT0WU
CAL-148 NFXHNnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGH2SoNKSzVyPUCuNFU1OzlizszN NVrxbWRFW0GQR1XS
CGTH-W-1 M2K5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzjTWM2OD1yLkC1OFQ6KM7:TR?= MnjJV2FPT0WU
NCI-H889 NYmxZXVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwMEW1PVIh|ryP Ml\RV2FPT0WU
GR-ST NXzlVJBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwMEW2NlEh|ryP NF;sRmpUSU6JRWK=
KARPAS-422 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlj1TWM2OD1yLkC1OlUh|ryP NYm3PFFiW0GQR1XS
RPMI-8866 NW[1c5pKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHUTWM2OD1yLkC1O|EzKM7:TR?= MYPTRW5ITVJ?
SCLC-21H MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\WOmlEPTB;MD6wOVg5PCEQvF2= M4rNb3NCVkeHUh?=
COR-L88 NFXzVVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnhRmxOUUN3ME2wMlA2QTJ5IN88US=> MlHxV2FPT0WU
LU-139 M4L1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnGXotKSzVyPUCuNFU6QDZizszN MlnwV2FPT0WU
SF126 NWTlOW44T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTMTWM2OD1yLkC2NVM{KM7:TR?= M2XHR3NCVkeHUh?=
NCI-H1882 M1[5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn60TWM2OD1yLkC2OFI1KM7:TR?= NF7FO3RUSU6JRWK=
EW-24 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwME[0PFMh|ryP M2m4WHNCVkeHUh?=
CP67-MEL MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\YSoJqUUN3ME2wMlA3QDFizszN NVzZUWQ1W0GQR1XS
DG-75 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmn2TWM2OD1yLkC2PFk6KM7:TR?= MoLNV2FPT0WU
LOXIMVI M33HSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[1WGlEPTB;MD6wO|AzQCEQvF2= NFH3VHVUSU6JRWK=
HH NXjmenBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DubmlEPTB;MD6wO|E2PyEQvF2= M4fIeHNCVkeHUh?=
K5 NH3FSWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LJcGlEPTB;MD6wO|IzPiEQvF2= NFf3PZdUSU6JRWK=
EC-GI-10 NUTtbIJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjXTWM2OD1yLkC3NlU4KM7:TR?= NU\DfG0{W0GQR1XS
SK-N-DZ Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwMEezNFch|ryP M1LBVHNCVkeHUh?=
A3-KAW MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnMTWM2OD1yLkC3N|UyKM7:TR?= MYTTRW5ITVJ?
MLMA MkXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwMEe0OlUh|ryP NITVT49USU6JRWK=
LB996-RCC NVnnNI5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml24TWM2OD1yLkC3O|A4KM7:TR?= MX\TRW5ITVJ?
OS-RC-2 NGLZb|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1KxXGlEPTB;MD6wO|c1QCEQvF2= NILWXZhUSU6JRWK=
CTB-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7kRZRKSzVyPUCuNFc5OSEQvF2= NFTQOJhUSU6JRWK=
IST-MES1 NU\WWJhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TwNmlEPTB;MD6wO|kyOiEQvF2= Moq1V2FPT0WU
LS-1034 NEfQ[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLDTWM2OD1yLkC4NFM2KM7:TR?= M3e4RXNCVkeHUh?=
HT M4XuRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\rTWM2OD1yLkC4NFg3KM7:TR?= MUDTRW5ITVJ?
NCI-H2141 NG\UbGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\BbIE3UUN3ME2wMlA5OSEQvF2= M{jjcXNCVkeHUh?=
LB2518-MEL MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFiwT49KSzVyPUCuNFgyPDFizszN NXXaXFNEW0GQR1XS
GI-ME-N MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnMclJnUUN3ME2wMlA5PDV{IN88US=> M4SyenNCVkeHUh?=
TGW MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn3TWM2OD1yLkC4OlA4KM7:TR?= MUjTRW5ITVJ?
SK-NEP-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnnNoxSUUN3ME2wMlA5PjRzIN88US=> NWrFeWVrW0GQR1XS
NOMO-1 NXnRcJNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTw[mpYUUN3ME2wMlA6Ojd3IN88US=> M3fOTnNCVkeHUh?=
ES6 NYTER4dyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkK3TWM2OD1yLkC5OVg6KM7:TR?= NX3zbohmW0GQR1XS
NCI-H209 M3[2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHRT4F6UUN3ME2wMlA6Pzh4IN88US=> NHfzd5BUSU6JRWK=
GAK MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHIO2FOUUN3ME2wMlExOTZizszN NV3LPWhkW0GQR1XS
BC-1 MlPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwMUCzOlEh|ryP Mn;nV2FPT0WU
KLE NUDQeJVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPkSIZRUUN3ME2wMlExPDR|IN88US=> NHHVTpVUSU6JRWK=
EW-3 M{[3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjMZY1KSzVyPUCuNVA6QCEQvF2= M13ZS3NCVkeHUh?=
NKM-1 NYDjV41HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULsNYpIUUN3ME2wMlEyOSEQvF2= MoW0V2FPT0WU
D-336MG MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXiOZJ7UUN3ME2wMlEyOjR2IN88US=> NWjjWWU6W0GQR1XS
NB69 NWf1TpVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTnXoRLUUN3ME2wMlEyOzBzIN88US=> NH7oSnFUSU6JRWK=
D-263MG MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HhVmlEPTB;MD6xNVcyOiEQvF2= M2fz[3NCVkeHUh?=
KP-N-YS M{e1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMUKyPVEh|ryP MXHTRW5ITVJ?
NCI-H1155 M2DqbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXJTWM2OD1yLkGyOVU5KM7:TR?= MVvTRW5ITVJ?
BOKU NYDFb25yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\jTWM2OD1yLkGyOVc6KM7:TR?= NHSxN45USU6JRWK=
LAMA-84 NXTxb3ZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULETIFZUUN3ME2wMlEzQTlizszN NGmy[nZUSU6JRWK=
Raji NUi4e3hqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\JR|k6UUN3ME2wMlE{OTF5IN88US=> NXjvR29zW0GQR1XS
LU-65 M3fBWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjIZ29KSzVyPUCuNVM{ODdizszN NXnme3dEW0GQR1XS
NCI-H187 NYDSOnhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojhTWM2OD1yLkGzPVI1KM7:TR?= NW\sWIlGW0GQR1XS
GCIY M4j5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzo[pdKSzVyPUCuNVQ6ODFizszN NV\STGVYW0GQR1XS
NCI-H2107 NYPCTINWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHzTWM2OD1yLkG1NFgh|ryP MYfTRW5ITVJ?
NCI-H1522 NYHCXIdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mor2TWM2OD1yLkG1NlY3KM7:TR?= NHroPZpUSU6JRWK=
NB6 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwMUW2NlMh|ryP NHe4OGZUSU6JRWK=
EM-2 M{TDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XGW2lEPTB;MD6xOVcxPiEQvF2= MUnTRW5ITVJ?
HCC2218 MoqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr3XWdNUUN3ME2wMlE2QThizszN NGSxR|BUSU6JRWK=
NCI-H748 M2fkVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwMU[zO|Yh|ryP MmXUV2FPT0WU
MS-1 NH;NcYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fRbmlEPTB;MD6xOlU{PyEQvF2= NEPHXYdUSU6JRWK=
NB5 NF7Md|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\GTWM2OD1yLkG2OVk4KM7:TR?= NGjCfHBUSU6JRWK=
OMC-1 M2Dlc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTGSWh{UUN3ME2wMlE3Pjh6IN88US=> M3u5OHNCVkeHUh?=
NCI-H345 MonSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHB[3ZKSzVyPUCuNVY6OjhizszN NWPBeGtKW0GQR1XS
L-428 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDxVIFKSzVyPUCuNVY6PDVizszN NGnvT3RUSU6JRWK=
SCH MmfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYf3TZhPUUN3ME2wMlE5Pjh3IN88US=> NEHsc4FUSU6JRWK=
NCI-H1417 M{[1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnk[2dzUUN3ME2wMlE6OjJ5IN88US=> MkHMV2FPT0WU
COLO-320-HSR NUPZRoFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMUm1N|Ih|ryP NVLrW2ZvW0GQR1XS
BT-474 M2j6Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnm1TWM2OD1yLkKwPFkzKM7:TR?= Mon4V2FPT0WU
GDM-1 NYXITWpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwMkG5O|Eh|ryP MljuV2FPT0WU
NCI-H2196 M4DEeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwMkKyN|Uh|ryP M{HM[nNCVkeHUh?=
KP-N-RT-BM-1 M4HQTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoqyTWM2OD1yLkKyN|Q6KM7:TR?= M3Pt[XNCVkeHUh?=
KNS-81-FD Ml;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnaTWM2OD1yLkKyPVU5KM7:TR?= NIm3WXFUSU6JRWK=
COLO-668 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEG2bJdKSzVyPUCuNlM3PzVizszN NF7BSpJUSU6JRWK=
C2BBe1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwMk[3OFch|ryP MnHwV2FPT0WU
Ramos-2G6-4C10 MknyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWWzNW1HUUN3ME2wMlI3QTV2IN88US=> NYfYTHpGW0GQR1XS
CAS-1 MmP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4q2TmlEPTB;MD6yO|A6PiEQvF2= M4PGenNCVkeHUh?=
GOTO M2HsSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIi4c|VKSzVyPUCuNlc5QTRizszN M1yzWnNCVkeHUh?=
LP-1 NYXHUXNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwMkiwOVch|ryP MlKzV2FPT0WU
NCI-SNU-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zoe2lEPTB;MD6yPVQzOiEQvF2= M1jlfHNCVkeHUh?=
EB-3 M1zxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMkm5O|kh|ryP MW\TRW5ITVJ?
MHH-NB-11 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjSfmFKSzVyPUCuN|A1ODJizszN NFLUN5dUSU6JRWK=
SK-N-FI MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfuWZVKSzVyPUCuN|E3QTJizszN MkizV2FPT0WU
HCC2157 Mmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDuTWM2OD1yLkOzPVE{KM7:TR?= M3q2e3NCVkeHUh?=
SIMA MorMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfGTWM2OD1yLkO0OVgyKM7:TR?= MmfBV2FPT0WU
MDA-MB-134-VI NFXYRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwM{[5Nlgh|ryP NF;kTFNUSU6JRWK=
NCI-H1694 NUTzemdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;l[HlKSzVyPUCuN|ch|ryP Mon3V2FPT0WU
EHEB NXjITo1DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHoOmdOUUN3ME2wMlM6ODh3IN88US=> NFXhVI9USU6JRWK=
U-266 NV7CblNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7MTWM2OD1yLkO5PFQ3KM7:TR?= MljaV2FPT0WU
LC-1F M1nTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwNEO3OlUh|ryP MoTTV2FPT0WU
SHP-77 MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUOyTHM4UUN3ME2wMlQ4QDV3IN88US=> NH3HdXBUSU6JRWK=
LS-513 MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwNEmzNFch|ryP MWTTRW5ITVJ?

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい
体内試験 The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

お薦めの試験操作（参考用のみ）

細胞試験：

[1]
+ 展開
  • 細胞株： Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • 濃度： 0.1-100 pM
  • 反応時間： 72 hours
  • 実験の流れ：

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (参考用のみ)
動物試験：

[5]
+ 展開
  • 動物モデル： Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • 製剤： Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • 投薬量： 20 mg/kg
  • 投与方法： Administered via i.v.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
体内 左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5% DMSO+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。 		2.5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 853.91
化学式

C47H51NO14
CAS No. 33069-62-4
保管 粉
in solvent
別名 NSC 125973

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

総分子量：g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03400306 Not yet recruiting Cancer - Ovarian AbbVie May 10 2020 Phase 1
NCT03704077 Not yet recruiting Gastric Cancer|Cancer of the Stomach|Stomach Cancer|Gastroesophageal Junction Bristol-Myers Squibb May 15 2019 Phase 2
NCT03199885 Not yet recruiting Breast Adenocarcinoma|HER2/Neu Positive|Recurrent Breast Carcinoma|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7 National Cancer Institute (NCI) May 10 2019 Phase 3
NCT03742986 Not yet recruiting Breast Cancer New York University School of Medicine April 2019 Phase 2
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic April 1 2019 Phase 1|Phase 2
NCT03725436 Not yet recruiting Advanced Malignant Solid Neoplasm|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Estrogen Receptor Positive|HER2/Neu Negative|Metastatic Malignant Solid Neoplasm|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Recurrent Breast Carcinoma|TP53 wt Allele|Unresectable Malignant Solid Neoplasm M.D. Anderson Cancer Center|National Cancer Institute (NCI) March 31 2019 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問（FAQ）

  • 質問1：

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • 回答：

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • 質問2：

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • 回答：

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

selleck catalog

Microtubule Associatedシグナル伝達経路

相関Microtubule Associated製品

  • TAI-1

    TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.

  • Docetaxel Trihydrate

    Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

  • Combretastatin A4

    Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

  • Docetaxel

    Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

  • Vincristine sulfate

    Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

  • Nocodazole

    Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively.

  • Vinorelbine Tartrate

    Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.

Tags: Paclitaxelを買う | Paclitaxel ic50 | Paclitaxel供給者 | Paclitaxelを購入する | Paclitaxel費用 | Paclitaxel生産者 | オーダーPaclitaxel | Paclitaxel化学構造 | Paclitaxel分子量 | Paclitaxel代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID